XALKORI 250 MG — DIN 02384264
CRIZOTINIB : 250 MG · PFIZER CANADA ULC · CAPSULE · wholesale supply in Canada
Health Canada status: MARKETED
What is XALKORI?
XALKORI 250 MG contains CRIZOTINIB : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02384264, held by PFIZER CANADA ULC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 10-May-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XALKORI used for?
Monotherapy for ALK-positive or ROS1-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Crizotinib cost around the world?
Crizotinib is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 1 | 4 | AUD███.██ |
| United Arab Emirates | public | 2 | 2 | AED███.██ |
| Czechia | max producer price (ex-factory) | 1 | 2 | CZK███.██ |
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
| Hungary | producer price (ex-factory) | 2 | 2 | HUF███.██ |
| Iceland | max wholesale | 1 | 2 | ISK███.██ |
| Italy | ex-factory (classe H) | 2 | 2 | EUR███.██ |
| Luxembourg | reimbursement | 2 | 2 | EUR███.██ |
| Romania | max producer price | 1 | 2 | RON███.██ |
| Saudi Arabia | public | 2 | 2 | SAR███.██ |
| South Africa | single exit price | 2 | 2 | ZAR███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
25 pack listings across 19 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Crizotinib pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Crizotinib in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Crizotinib — 2 DINs, of which 2 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 2 | 2 | XALKORI | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 250 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 60 capsules and PVC/aluminum foil blisters containing 60 capsules (6 cards of 10). |
| Storage | Not explicitly stated in the provided text (section 11 is in TOC but content not in snippet). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Crizotinib |
|---|---|
| ATC code | L01ED01 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02384264 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2384264 |
| Brand name | XALKORI |
| Generic / active ingredient | CRIZOTINIB : 250 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | L01ED01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01ED |
| Current status | MARKETED |
| Status date | 10-May-2012 |
| Original market date | 2012-05-10 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Recommended dose is 250 mg orally twice daily. Adjustments required for hepatic/renal impairment and toxicities. Capsules must be swallowed whole.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Congenital long QT syndrome; persistent QTcF ≥500 msec; known hypersensitivity to crizotinib or any ingredient in the formulation.
Warnings and precautions
QT interval prolongation, bradycardia, hepatotoxicity (including fatal), interstitial lung disease/pneumonitis (including fatal), severe vision loss, and cardiac failure.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| XALKORI | 200 MG | CAPSULE | PFIZER CANADA ULC | MARKETED | 02384256 |
2 · Same class — other molecules in ATC L01ED
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Brigatinib | ALUNBRIG | 4 | 4 | Yes |
| Crizotinib | XALKORI | 2 | 2 | Yes |
| Lorlatinib | LORBRENA | 2 | 2 | Yes |
| Alectinib | ALECENSARO | 1 | 1 | Yes |
| Ceritinib | ZYKADIA | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01E
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01EX | Avapritinib · Cabozantinib · Capivasertib · Capmatinib · Entrectinib · Gilteritinib · Larotrectinib · Lenvatinib · Midostaurin · Nintedanib · Other Protein Kinase Inhibitors · Pazopanib · Pralsetinib · Quizartinib · Regorafenib · Repotrectinib · Ripretinib · Selpercatinib · Sorafenib · Sunitinib · Tepotinib · Vandetanib | 80 | 64 |
| L01EA | Asciminib · Bosutinib · Dasatinib · Imatinib · Nilotinib · Ponatinib | 73 | 57 |
| L01EB | Afatinib · Dacomitinib · Erlotinib · Gefitinib · Lazertinib · Osimertinib | 40 | 23 |
| L01EF | Abemaciclib · Palbociclib · Ribociclib | 17 | 14 |
| L01EJ | Fedratinib · Momelotinib · Ruxolitinib | 8 | 8 |
| L01EE | Binimetinib · Cobimetinib · Selumetinib · Trametinib | 8 | 7 |
| L01EN | Erdafitinib · Infigratinib · Pemigatinib | 11 | 6 |
| L01EL | Acalabrutinib · Ibrutinib · Zanubrutinib | 10 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is XALKORI called?
Also recorded in Canada as: crizotinib 200 MG Oral Capsule [Xalkori] (US), crizotinib 250 MG Oral Capsule [Xalkori] (US), crizotinib 150 MG Oral Pellet [Xalkori] (US), crizotinib 20 MG Oral Pellet [Xalkori] (US), crizotinib 50 MG Oral Pellet [Xalkori] (US), crizotinib 200 MG Oral Capsule (US), crizotinib 250 MG Oral Capsule (US), crizotinib 150 MG Oral Pellet (US), crizotinib 20 MG Oral Pellet (US), crizotinib 50 MG Oral Pellet (US), CRIZOTINIB (US).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.